• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Facebook
  • Instagram
  • LinkedIn
  • TikTok
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact
  • Spanish
  • English

Researchers have identified antibodies that could defeat all coronaviruses

Inicio » Noticias UE » Sanidad » Diseases » Researchers have identified antibodies that could defeat all coronaviruses

14 de February de 2023

científica siendo rodeada de virus

Researchers have identified antibodies that not only block infection with the latest variant of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), but are also effective against future coronaviruses.

With the evolution of SARS-CoV-2, the efficacy of vaccines and antibodies is reduced in the laboratory. So how can a treatment be developed that resists virus evolution? With this goal in mind, an international team of researchers, supported in part by the EU-funded ATAC project, set out to determine whether the entire coronavirus evolves or whether parts of it remain the same. The researchers hypothesised that some parts of the virus may be forced to remain unchanged in order to function or maintain a proper structure. To test whether this was true, they analysed approximately 10.5 million SARS-CoV-2 sequences. As described in a paper published in Science Immunology, the researchers found that parts of the coronavirus spike protein that allow the virus to enter host cells and cause infection are highly conserved. “We call them ‘cold spots’,” says study leader Virginia Crivelli of the Swiss Institute for Biomedical Research (IRB), a partner in the ATAC project, in a press release published in EurekAlert! “Most viruses change rapidly, but we found 15 regions that did not change,” continued the PhD student.

Facilitating travel during the pandemic: the EU Digital COVID certificate worked

Finding the right types of antibodies

The team analysed samples taken from people who had recovered from COVID-19 and found that some of them had specific antibodies against the cold spot. “These antibodies are very rare,” says Filippo Bianchini, co-author of the study and IRB PhD student, “but we were able to find them using a new method. The approach, called “cold-spot-guided antibody discovery”, is a detection method that targets parts of the coronavirus spike-in protein that the study describes as “functionally related and resistant to disruption”.

Blocking and protecting

In the lab experiments conducted, these rare coldspot-specific antibodies were able to block viral infection even by the latest variants of concern. They also provided protection from disease in preclinical models. The question now is whether the newly discovered antibodies will have any effect against SARS-CoV-2 variants and coronaviruses that have yet to appear. “It is likely that new coronaviruses that infect humans will emerge,” observes IRB director and study senior author Dr Davide Robbiani in the same news release. As the researcher goes on to say, “our findings indicate that it may be already possible to develop countermeasures that are broadly effective against present and also future coronaviruses.” The ATAC (Antibody therapy against coronavirus (COVID-19)) project has built on previous experience of SARS- and MERS-CoV antibody therapy to develop passive immunotherapy against COVID-19. Besides providing a human antibody candidate for therapy, ATAC will also rapidly disseminate results to help the medical community respond to the pandemic.

More information

CORDIS

Publicaciones relacionadas:

Proyecto MEDIWARN CoronavirusMedical sensors boost response to Italy’s COVID-19 crisis First EIC COVID-19 Response certificates Commission launches one-stop shop for coronavirus research and innovation funding Coronavirus: additional €122 million for research and innovation banderas europeasThe European Commission will address the issue of Coronavirus at its meeting on 5th March

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas

Proyecto MEDIWARN CoronavirusMedical sensors boost response to Italy’s COVID-19 crisis First EIC COVID-19 Response certificates Commission launches one-stop shop for coronavirus research and innovation funding Coronavirus: additional €122 million for research and innovation banderas europeasThe European Commission will address the issue of Coronavirus at its meeting on 5th March

Footer

Logotipo en negativo del Centro de Documentación Europea de Almería
  • CDE Almería
  • Edificio Parque Científico-Tecnológico (Pita)
  • Planta: 1ª, Despacho: 2904120.
  • Ctra. Sacramento s/n. Almería (Spain)
  • Teléfono: (+34) 950 015266

HOME
NEWS
DOCUMENTATION
EUROPE ON THE NET
ABOUT US

  • LEGAL NOTICE
  • PRIVACY POLICY
  • COOKIE POLICY
  • ACCESSIBILITY
  • SITEMAP

Copyright © 2023 CDE Almería · Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

<p>El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. ajustes</p>

Politica de privacidad

El Centro de Documentación Europea de la Universidad de Almería utiliza cookies propias y de terceros para facilitar al usuario la navegación en su página Web y el acceso a los distintos contenidos alojados en la misma. Asimismo, se utilizan cookies analíticas de terceros para medir la interacción de los usuarios con el sitio Web. Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. <a href="/politica-de-cookies" rel="noopener" target="_blank">Más información</a>

Cookies estrictamente necesarias

Las cookies estrictamente necesarias tiene que activarse siempre para que podamos guardar tus preferencias de ajustes de cookies.

Básicamente la web no funcionara bien si no las activas.

Estas cookies son:

  • Comprobación de inicio de sesión.
  • Cookies de seguridad.
  • Aceptación/rechazo previo de cookies.

Si desactivas esta cookie no podremos guardar tus preferencias. Esto significa que cada vez que visites esta web tendrás que activar o desactivar las cookies de nuevo.

Cookies de terceros

Esta web utiliza Google Analytics, Google Tag Manager y Yandex Metrika para recopilar información anónima tal como el número de visitantes del sitio, o las páginas más populares.

Dejar estas cookies activas nos permite mejorar nuestra web.

¡Por favor, activa primero las cookies estrictamente necesarias para que podamos guardar tus preferencias!

Política de cookies

Pinche el siguiente enlace si desea información sobre el uso de cookies y como deshabilitarlas. Más información